DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Yurdaydin C, Idilman R, Keskin O. et al.
A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis – end of treatment results from the LOWR HDV-2 study.
Journal Of Hepatology 2017;
66: S33-S34
We do not assume any responsibility for the contents of the web pages of other providers.